Stock Events

Stock Events

Autolus Therapeutics 

$1.7250
75
+$0.10+6.48% Today

Statistics

Day High
1.725
Day Low
1.635
52W High
2.68
52W Low
1.21
Volume
1,702,055
Avg. Volume
-
Mkt Cap
459.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

12AugExpected
Q4 2023
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-0.45
-0.32
-0.18
-0.05
Expected EPS
-0.24
Actual EPS
-0.18

Financials

-2,180.45%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
20.24MRevenue
-441.32MNet Income

Analyst Ratings

10.00Average Price Target
The highest estimate is 10.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AUTL. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap166.9B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, making it a direct competitor in the oncology treatment market.
Novartis
NVS
Mkt Cap286.54B
Novartis is a major player in the CAR-T space with approved therapies, competing in the same advanced cancer treatment market as Autolus.
CRISPR Therapeutics
CRSP
Mkt Cap5.42B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to CAR-T therapy, making it a competitor in the gene therapy market.
Allogene Therapeutics
ALLO
Mkt Cap748.99M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, which are off-the-shelf, directly competing with Autolus' personalized approach.
Precigen
PGEN
Mkt Cap1.55B
Precigen focuses on next-generation gene and cell therapies, including CAR-T, making it a competitor in the advanced therapeutic space.

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Christian Martin Itin Ph.D.
Employees
647
Country
United Kingdom
ISIN
US05280R1005

Listings

STU
DE
6A3A.STU
MU
DE
6A3A.MU
XNAS
US
AUTL
F
DE
6A3A.F

0 Comments

Share your thoughts

FAQ

What is Autolus Therapeutics stock price today?▼
The current price of AUTL is $1.73 USD — it has increased by +6.48% in the past 24 hours. Watch Autolus Therapeutics stock price performance more closely on the chart.
What is Autolus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Autolus Therapeutics stocks are traded under the ticker AUTL.
Is Autolus Therapeutics stock price growing?▼
AUTL stock has fallen by -2.54% compared to the previous week, the month change is a +9.87% rise, over the last year Autolus Therapeutics has showed a -17.46% decrease.
What is Autolus Therapeutics market cap?▼
Today Autolus Therapeutics has the market capitalization of 459.1M
What were Autolus Therapeutics earnings last quarter?▼
AUTL earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.24 USD resulting in a +25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Autolus Therapeutics revenue for the last year?▼
Autolus Therapeutics revenue for the last year amounts to 20.24M USD.
What is Autolus Therapeutics net income for the last year?▼
AUTL net income for the last year is -441.32M USD.
How many employees does Autolus Therapeutics have?▼
As of June 04, 2026, the company has 647 employees.
In which sector is Autolus Therapeutics located?▼
Autolus Therapeutics operates in the Health & Wellness sector.
When did Autolus Therapeutics complete a stock split?▼
Autolus Therapeutics has not had any recent stock splits.
Where is Autolus Therapeutics headquartered?▼
Autolus Therapeutics is headquartered in London, United Kingdom.